Code intelligence

FDA-NDA021132 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance referencing code FDA-NDA021132.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated

Critical

High

100%

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: LINEZOLID (LINEZOLID) — Type 3 - New Dosage Form

Policy FDA-NDA021132 · Infectious Disease

High

Linezolid for suspension is an oral medication that will be billed under Medicare Part D. Since it does not have an injectable form, there will be no assignment of J-codes. Billing teams should monito

View alert